With ongoing discussions of the use of surrogate biomarkers, the utility of liquid biopsy for sample collection, and Prof Ribas’ proposed combinations of BRAF, MEK and anti-PD1 therapy for melanoma, there seems little room for any tumour cells escaping. This evidence concerns the gene MAP2K7 and neoplasm.